Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | Suppliers

Lallemand Pharma - Lyophilized Bacterial Lysates for Immuno-Protection Solutions

Based in Zug (Switzerland), Lallemand Pharma International (LPI) is a pharmaceutical subsidiary of the Lallemand group. LPI is in charge of the business and possesses the intellectual property rights of an oral vaccine indicated in the prevention of respiratory infections known as PMBL.

Developing & marketing all around the world drugs containing PMBLTM tablets

Lallemand Pharma AG, subsidiary of LPI, based in Lugano (Switzerland) is dedicated exclusively to the clinical studies, registrations, marketing and sales of this PMBL drug.

lallemand

Thanks to its important distributor's network consisting of leading international pharmaceutical companies, the core business of Lallemand Pharma is to develop and market all around the world drugs containing PMBL tablets under different brands.

Lallemand Pharma AG works in a B to B model and provides with key turn PMBL tablets to leading International Pharmaceutical companies.

Our PMBL tablets, made of bacterial lysates obtained by unique mechanical lysis process, are distributed worldwide:

  • EUROPE: Italy, Greece, Poland, Portugal
  • EASTERN EUROPE: Ukraine, CIS countries
  • ASIA: India, South Korea, Sri-Lanka
  • LATAM: Mexico, Argentina, Uruguay, Venezuela, Péru, Honduras, Guatemala, El-Salvador and Ecuador

Registrations are on-going in ROW countries.

To obtain more information you can connect at: www.lallemandpharma.com

Contact

LALLEMAND PHARMA AG
Piazza Molino Nuovo 17
C.P. 5183
6901 Lugano
Switzerland
Phone: +41 91 98 04 613
Email: marketinglp@lallemand.com
URL: www.lallemandpharma.com